Summary
The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.
Novo drops ‘Nordisk’ in corporate refresh to take on Lilly in the weight-loss wars
Source & full coverage: this summary is aggregated from MarketWatch, the original publisher. Read the complete report for full context, data and quotes.
Read the original report at MarketWatch →
